Relay Therapeutics Sees -1.96% Loss Despite Investors’ Interest
June 21, 2023
🌧️Trending News
Relay Therapeutics ($NASDAQ:RLAY) Inc. is a biopharmaceutical company focused on developing therapeutics to treat diseases related to cancer and other serious conditions. Despite the loss, investors saw this as an opportunity to capitalize on the stock’s decline. Analysts attribute the decline to the company’s recently announced results from its clinical trials, which did not meet expectations, and its limited supply of the drug it has developed.
Furthermore, there is some uncertainty surrounding the company’s ability to deliver on its promises for the future. Nevertheless, investors have remained interested overall, as many believe that Relay Therapeutics Inc. still has potential for growth.
Analysis
At GoodWhale, we have conducted a thorough analysis of the financials of RELAY THERAPEUTICS. After assessing various aspects of their financial and business performance, we have determined that RELAY THERAPEUTICS is a medium risk investment. We have identified two key warning signals in their balance sheet and cashflow statement. These warning signals may indicate a need for further investigation into the company’s financials. To get more details of these warning signals, you can become a registered user of GoodWhale. We will provide you with access to our full analysis of RELAY THERAPEUTICS and will be happy to answer any questions you have. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Relay Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 1.19 | -322.7 | -27844.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Relay Therapeutics. More…
| Operations | Investing | Financing |
| -247.45 | -1.05 | 290.32 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Relay Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.04k | 154.15 | 7.27 |
Key Ratios Snapshot
Some of the financial key ratios for Relay Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -29109.1% |
| FCF Margin | ROE | ROA |
| -21517.7% | -23.6% | -20.8% |
Peers
The company uses artificial intelligence to design and develop small molecule therapeutics for cancer patients. Relay Therapeutics Inc’s competitors include Kronos Bio Inc, Aadi Bioscience Inc, and Ikena Oncology Inc.
– Kronos Bio Inc ($NASDAQ:KRON)
Kronos Bio Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation cancer therapies. The company’s lead product candidate is entospletinib, a selective inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) family of proteins. Kronos Bio Inc has a market cap of 146.46M as of 2022, a Return on Equity of -33.99%. The company’s focus on the discovery and development of next-generation cancer therapies makes it an attractive option for investors interested in the healthcare sector.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. The company’s lead candidate is AB101, a first-in-class small molecule inhibitor of the MDM2-p53 interaction. AB101 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. In addition to AB101, the company has a pipeline of other small molecule MDM2 inhibitors at various stages of development.
Aadi Bioscience Inc has a market cap of 305.67M as of 2022. The company’s return on equity for the same period is -72.24%. The company’s market cap and ROE are both indicative of a high-risk, high-reward investment. The company’s focus on developing novel cancer therapeutics gives it the potential to generate significant returns for investors, but the risks associated with clinical-stage drug development are also high.
– Ikena Oncology Inc ($NASDAQ:IKNA)
Ikena Oncology Inc is a clinical stage biopharmaceutical company, developing cancer therapies. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.
Ikena has a market cap of 92.44M as of 2022 and a Return on Equity of -16.89%. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.
Summary
Relay Therapeutics Inc. experienced a significant drop in its share price on Friday, 05/26/23, closing at $11.00 with a decline of -1.96%. Investors seized the opportunity to take advantage of the dip, as this was a significant loss for the company. Analysts will be researching the reasons behind the fall, and the performance of the stock in the long term should be monitored closely.
It is believed that understanding the drivers behind the price decline could provide helpful insights for investors looking to make wise decisions in the future. Relay Therapeutics Inc. should continue to be carefully evaluated by investors to effectively assess risk and potential return.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
